HAVCR2 and breast carcinoma: However, TIM-3 and TIGIT targeting are still early in clinical research, and few reports of the therapeutic efficacy of anti-TIGIT or anti-TIM-3 including combinatorial therapies (TIGIT ICI or TIM-3 ICI plus PD-1(L1) ICI) are available in breast cancer to date.